Alicia Avis-Bodas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alicia Avis-Bodas has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alberto García-Redondo
Neurology Department, ALS Unit, Hospital 12 de Octubre Health Research Institute (i+12), CIBERER U-723 (Instituto de Salud Carlos III), Avenida Córdoba, s/n , 28041 Madrid, Spain
1 shared publication Ana Ramos
Department of Radiology Hospital Universitario 12 de Octubre Madrid Spain
1 shared publication- Angel Perez-Nuñez
Department of Neurosurgery, Hospital Universitario 12 de Octubre, Department of Surgery, Medical School Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) Madrid Spain
1 shared publication - Aurelio Hernández-Laín
Department of Neuropathology, Hospital Universitario 12 de Octubre, Madrid, Spain
1 shared publication - Beatriz Herranz
Medical School Universidad Francisco de Vitoria Madrid Spain
1 shared publication - Berta Segura-Collar
Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 5 May 2026
- Published by Wiley in Brain Pathology
- Vol. 36 (6) , e70106
Patient‐derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones
Glioblastoma (GBM) is one of the deadliest cancers, largely due to its nearly inevitable recurrence driven by residual tumor cells. Recent evidence suggests that performing supratotal resections that extend into non‐contrast‐enhancing (nCE) tumor regions may prolong survival. However, tumor infiltration in these areas has not been fully characterized. Our goal was to define the cellular landscape of the GBM periphery and its clinical relevance. To accomplish this, we prospectively collected 161 biopsies from 45 GBM patients. The samples were classified using magnetic resonance imaging (MRI) as either enhancing tumor, nCE tumor, vasogenic edema, or radiologically normal tissue. We performed immunohistochemistry with MIB1 staining to detect proliferative cells and measure cell density. We also performed transcriptional profiling, selecting immune, glial, and vascular markers from single‐cell RNA sequencing data. We analyzed the associations with the extent of resection and patient outcomes. Most nCE tumor biopsies displayed neoplastic features, including high cellularity, proliferative markers, and loss of oligodendrocyte signatures. However, some regions labeled as edema by MRI also contained infiltrating tumor cells and were associated with disease progression. Therefore, although MRI‐based classification of nCE tumor regions is generally accurate, it underestimates infiltration within edema‐labeled areas. Furthermore, in patients who underwent gross‐total resection, high peripheral cellularity predicted earlier local recurrence. This suggests that assessing cell density in the periphery can improve recurrence risk prediction. Regarding the tumor microenvironment analysis, immune‐related phenotypes were associated with a worse prognosis only after complete resection of the enhancing tumor. Furthermore, our gene panel, particularly the oligodendrocyte markers, provides prognostic insights depending on both biopsy location and resection extent. These findings support the integration of histological and molecular evaluations of the tumor periphery into surgical and therapeutic decision‐making processes. This approach offers a path to better patient stratification and outcome prediction in GBM.
- 5 May 2026
- Published by Wiley in Brain Pathology
- Vol. 36 (6) , e70106
Open AccessPatient‐derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones
Glioblastoma (GBM) is one of the deadliest cancers, largely due to its nearly inevitable recurrence driven by residual tumor cells. Recent evidence suggests that performing supratotal resections that extend into non‐contrast‐enhancing (nCE) tumor regions may prolong survival. However, tumor infiltration in these areas has not been fully characterized. Our goal was to define the cellular landscape of the GBM periphery and its clinical relevance. To accomplish this, we prospectively collected 161 biopsies from 45 GBM patients. The samples were classified using magnetic resonance imaging (MRI) as either enhancing tumor, nCE tumor, vasogenic edema, or radiologically normal tissue. We performed immunohistochemistry with MIB1 staining to detect proliferative cells and measure cell density. We also performed transcriptional profiling, selecting immune, glial, and vascular markers from single‐cell RNA sequencing data. We analyzed the associations with the extent of resection and patient outcomes. Most nCE tumor biopsies displayed neoplastic features, including high cellularity, proliferative markers, and loss of oligodendrocyte signatures. However, some regions labeled as edema by MRI also contained infiltrating tumor cells and were associated with disease progression. Therefore, although MRI‐based classification of nCE tumor regions is generally accurate, it underestimates infiltration within edema‐labeled areas. Furthermore, in patients who underwent gross‐total resection, high peripheral cellularity predicted earlier local recurrence. This suggests that assessing cell density in the periphery can improve recurrence risk prediction. Regarding the tumor microenvironment analysis, immune‐related phenotypes were associated with a worse prognosis only after complete resection of the enhancing tumor. Furthermore, our gene panel, particularly the oligodendrocyte markers, provides prognostic insights depending on both biopsy location and resection extent. These findings support the integration of histological and molecular evaluations of the tumor periphery into surgical and therapeutic decision‐making processes. This approach offers a path to better patient stratification and outcome prediction in GBM.
- Open Access
- 9 March 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (3) , 671
CdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing
CdSe quantum dots (QDs) are valuable tools for deciphering molecular mechanisms in cells. Their conjugation with antibodies offers a unique staining source with optimal characteristics, including increased photostability and narrow emission spectra, allowing for improved multiplexing capabilities using a single excitation source. In combination with pathology models derived from patients, they have great potential to contribute to quantitative molecular profiling and promote personalized medicine. However, the commercial availability of diverse CdSe QDs is still limited and characterization techniques must be performed to these materials or the conjugates developed in the lab to assure a proper function and reproducibility. Furthermore, while there is significant data of QDs experiments in cell lines, the literature with primary human cells is scarce, and QD behavior in these systems may be different. Rigorous characterization data of commercially available QDs and their conjugates with biomolecules of interest is needed in order to establish their potential for target labelling and expand their use among research labs. Here we compare the characterization and labelling performance of different QD conjugates in SH-SY5Y cell line, fibroblasts and immortalized lymphocytes derived from amyotrophic lateral sclerosis patients.
- 9 March 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (3) , 671
Open AccessCdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing
CdSe quantum dots (QDs) are valuable tools for deciphering molecular mechanisms in cells. Their conjugation with antibodies offers a unique staining source with optimal characteristics, including increased photostability and narrow emission spectra, allowing for improved multiplexing capabilities using a single excitation source. In combination with pathology models derived from patients, they have great potential to contribute to quantitative molecular profiling and promote personalized medicine. However, the commercial availability of diverse CdSe QDs is still limited and characterization techniques must be performed to these materials or the conjugates developed in the lab to assure a proper function and reproducibility. Furthermore, while there is significant data of QDs experiments in cell lines, the literature with primary human cells is scarce, and QD behavior in these systems may be different. Rigorous characterization data of commercially available QDs and their conjugates with biomolecules of interest is needed in order to establish their potential for target labelling and expand their use among research labs. Here we compare the characterization and labelling performance of different QD conjugates in SH-SY5Y cell line, fibroblasts and immortalized lymphocytes derived from amyotrophic lateral sclerosis patients.